[go: up one dir, main page]

WO2023004415A3 - Sars-cov-2 vaccine using bacterial spores expressing antigenic fragments - Google Patents

Sars-cov-2 vaccine using bacterial spores expressing antigenic fragments Download PDF

Info

Publication number
WO2023004415A3
WO2023004415A3 PCT/US2022/074048 US2022074048W WO2023004415A3 WO 2023004415 A3 WO2023004415 A3 WO 2023004415A3 US 2022074048 W US2022074048 W US 2022074048W WO 2023004415 A3 WO2023004415 A3 WO 2023004415A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
cov
sars
bacterial spores
antigenic fragments
Prior art date
Application number
PCT/US2022/074048
Other languages
French (fr)
Other versions
WO2023004415A2 (en
Inventor
Mehdi MIRSAEIDI
Abdolrazagh Hashemi SHAHRAKI
Mohammad VAHED
Original Assignee
University Of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Miami filed Critical University Of Miami
Publication of WO2023004415A2 publication Critical patent/WO2023004415A2/en
Publication of WO2023004415A3 publication Critical patent/WO2023004415A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Disclosed are compositions comprising a SARS-CoV-2 vaccine that can be administered orally. The vaccine can be on a platform comprising a spore coat protein from a spore forming bacteria, such as Bacillus subtilis. Also disclosed are methods of preventing or treating a COVID-19 infection comprising providing the SARS-CoV-2 vaccine to a subject.
PCT/US2022/074048 2021-07-22 2022-07-22 Sars-cov-2 vaccine using bacterial spores expressing antigenic fragments WO2023004415A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163224638P 2021-07-22 2021-07-22
US63/224,638 2021-07-22

Publications (2)

Publication Number Publication Date
WO2023004415A2 WO2023004415A2 (en) 2023-01-26
WO2023004415A3 true WO2023004415A3 (en) 2023-03-02

Family

ID=84978769

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/074048 WO2023004415A2 (en) 2021-07-22 2022-07-22 Sars-cov-2 vaccine using bacterial spores expressing antigenic fragments

Country Status (1)

Country Link
WO (1) WO2023004415A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
TW202333780A (en) * 2021-11-29 2023-09-01 德商拜恩技術股份公司 Coronavirus vaccine
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050221423A1 (en) * 2002-04-10 2005-10-06 Andersen Jens T Bacillus host cell
KR102157964B1 (en) * 2019-06-13 2020-09-22 (주)제이비바이오텍 African swine fever vaccine of porcine using CRISPR/Cas9 based Bacillus subtilis genome editing mechanism
WO2021019102A2 (en) * 2019-08-01 2021-02-04 Acm Biolabs Pte Ltd A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomes
US11054429B1 (en) * 2020-03-25 2021-07-06 National University Of Singapore SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein binding

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050221423A1 (en) * 2002-04-10 2005-10-06 Andersen Jens T Bacillus host cell
KR102157964B1 (en) * 2019-06-13 2020-09-22 (주)제이비바이오텍 African swine fever vaccine of porcine using CRISPR/Cas9 based Bacillus subtilis genome editing mechanism
WO2021019102A2 (en) * 2019-08-01 2021-02-04 Acm Biolabs Pte Ltd A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomes
US11054429B1 (en) * 2020-03-25 2021-07-06 National University Of Singapore SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein binding

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEE SANGUN, BELITSKY BORIS R., BRINKER JAMES P., KERSTEIN KATHRYN O., BROWN DAVID W., CLEMENTS JOHN D., KEUSCH GERALD T., TZIPORI : "Development of a Bacillus subtilis -Based Rotavirus Vaccine", CLINICAL AND VACCINE IMMUNOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 17, no. 11, 1 November 2010 (2010-11-01), pages 1647 - 1655, XP093040557, ISSN: 1556-6811, DOI: 10.1128/CVI.00135-10 *

Also Published As

Publication number Publication date
WO2023004415A2 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
WO2023004415A3 (en) Sars-cov-2 vaccine using bacterial spores expressing antigenic fragments
MX2022015272A (en) Inhibitors of kras g12c protein and uses thereof.
EP4295902A3 (en) Probiotic bacterial strains producing antimicrobial proteins and compositions comprising these for use in the treatment of clostridium difficile infection
WO2018158306A8 (en) Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
MX2021002719A (en) Cannabinoids for the treatment of gram-positive infections including antibiotic-resistant bacterial strains.
MX2020009736A (en) Compositions comprising bacterial strains.
WO2022067052A8 (en) Probiotic bacillus compositions and methods of use
MX2020006191A (en) Therapeutic bacteriocins.
PH12019501904A1 (en) Macrocyclic broad spectrum antibiotics
WO2020146700A8 (en) Lipid nanoparticles
WO2020102901A8 (en) Synthetic antibacterial compounds and uses thereof
MX2021005421A (en) C11-cyclic substituted 13-membered macrolides and uses thereof.
WO2021004958A3 (en) Compositions comprising bacterial strains
WO2020165057A8 (en) Compositions containing bacillaene producing bacteria or preparations thereof
MX2021005423A (en) C10-alkylene substituted 13-membered macrolides and uses thereof.
MX2025000629A (en) Lactobacillus salivarius strains and uses thereof
MX2017007969A (en) Lactic acid bacteria and their use for the treatment of mastitis.
WO2022104002A3 (en) Sars-cov-2 immunodominant peptide constructs and uses thereof
MX2019006086A (en) Use of a bacterial composition for treating foot infections of ungulates.
WO2022011271A3 (en) Probiotics for use in the prevention or treatment of illness and/or symptoms associated with coronaviruses
MX2023006087A (en) Lyophilized formulations of tegavivint.
MX2022003871A (en) IMMUNOGENIC COMPOSITIONS.
ZA202100231B (en) Non-viable bifidobacterium bifidum bacteria and uses thereof
WO2020120716A8 (en) Compositions comprising bacterial strains
WO2018236086A3 (en) Novel aeromonas hydrophila bacteriophage aer-hyp-2 and use thereof in preventing proliferation of aeromonas hydrophila

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22846854

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22846854

Country of ref document: EP

Kind code of ref document: A2